Alterations of fecal short-chain fatty acids solely in the course of multiple sclerosis: rethinking the gut–brain axis in the early stages of MS
The findings indicate that reduction in SCFA levels is exclusively observed in patients with RRMS during the further course of the disease and not at the onset. Decrease in SCFA concentration may be rather consequence or related to neurodegeneration than linked to the first demyelinating event. Further investigation related to disease trajectories of immunomodulatory or neuroprotective treatments are required.
Authors
- Andreas Schwiertz (ORCID: https://orcid.org/0000-0002-2876-2352)
- Sergiu Groppa (ORCID: https://orcid.org/0000-0002-2551-5655)
- Mathias Fousse (ORCID: https://orcid.org/0000-0001-5489-1492)
- Niklas Kämpfer
- Anouck Becker (ORCID: https://orcid.org/0000-0003-2465-2276)
- Marcus M. Unger (ORCID: https://orcid.org/0000-0003-0805-6968)
- Jakob Stögbauer (ORCID: https://orcid.org/0000-0003-3311-2546)
Institutions
- Universitätsklinikum des Saarlandes (DE)
- Sonneberg Observatory (DE)
- Klinikum Saarbrücken (DE)
- Saarland University (DE)
Publication Details
- Journal
- Therapeutic Advances in Neurological Disorders
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17562864251396028
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00